Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Diagnosis involves blood, urine, and bone marrow tests, with ...

The proposed recommendations are intended to safely expedite approvals of promising therapies for multiple myeloma, but one expert is skeptical about the likelihood of industry compliance.

Halozyme Therapeutics (NASDAQ:HALO) executives highlighted what they described as a “significant and value-creating” 2025, ...

As I look back on the past year, it is clear that 2025 was one of the most significant and value-creating years in Halozyme ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026 Halozyme Therapeutics, Inc.

Company Announcement COPENHAGEN, Denmark; February 17, 2026 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025 ...

Despite being innate and immutable, queerness can often feel out of reach in our youth. For some, being gay, despite being an instinctual identity, means little personally until that queerness is ...

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the treatment of ...

Caring for someone with multiple myeloma can be challenging on many levels. The person who has just been diagnosed may look to you for information to help them better understand the disease to ...

In a new study published in Cancer, researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine’s Department of Pathology examine this disparity more closely, ...